Lindemann and co-workers demonstrated how additional usage of COTI-2 resulted in a higher sensitivity to cisplatin and radiation in head and neck squamous cell carcinoma (HNSCC), regardless of TP53 status [76]. This evidence concerns the gene TP53 and head and neck squamous cell carcinoma.